Biomx Inc (PHGE) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.68 (-5.42%), Market cap $0.01B, 52-week low–high $0.26 ~ $7.50.
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infection
Financial statements, price targets, institutional (13F) holdings and related news for Biomx Inc are updated in real time on BlackAll Trade.
Biomx Inc trades at $0.68 (-5.42%). Real-time quotes and charts are available on BlackAll Trade.
Biomx Inc has a market cap of about $0.01B.
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated